Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer.

ABSTRACT:

Importance

Although immune checkpoint inhibitors (ICIs), such as anti-PD-1 (programmed cell death 1) or anti-PD-L1 (programmed cell death 1 ligand 1), have proved effective in treating many cancers, patients receiving ICIs may experience immune-related adverse events (irAEs). Little evidence exists on the safety of resuming these treatments after an irAE.

Objective

To investigate the safety of a rechallenge with anti-PD-1 or anti-PD-L1 immunotherapies after an irAE.

Design, setting, and participants

This cohort study of the safety of an ICI rechallenge involved consecutive adult patients (n = 93) who were referred to the ImmunoTOX assessment board at the Gustave Roussy cancer center in Villejuif, France, between August 1, 2015, and December 31, 2017. Data were analyze

SUBMITTER: Simonaggio A 

PROVIDER: S-EPMC6555478 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature